Financiere de Tubize SA banner

Financiere de Tubize SA
XBRU:TUB

Watchlist Manager
Financiere de Tubize SA Logo
Financiere de Tubize SA
XBRU:TUB
Watchlist
Price: 225.5 EUR -0.66% Market Closed
Market Cap: €10B

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
€0
/
€0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
€0
/
€0

Peer Comparison

Country Company Market Cap Net
Margin
BE
Financiere de Tubize SA
XBRU:TUB
10B EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
997.2B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
578.6B USD
Loading...
CH
Roche Holding AG
SIX:ROG
281.1B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
303.5B USD
Loading...
CH
Novartis AG
SIX:NOVN
230.9B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
216.1B GBP
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK
Loading...
US
Pfizer Inc
NYSE:PFE
154.7B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
125.6B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Financiere de Tubize SA
Glance View

Market Cap
10B EUR
Industry
Pharmaceuticals

Nestled in the heart of Belgium, Financiere de Tubize SA stands as a distinctive player in the world of investment holding companies, anchored in its robust shareholding strategy. Unlike many investment entities that diversify their portfolios across industries, Tubize has channeled its focus largely into the pharmaceutical sector through its significant shareholding in UCB, a global biopharmaceutical giant. This singular focus reflects a strategic commitment to capitalize on the growth and innovations within the healthcare industry, leveraging UCB's extensive research capabilities and expansive market presence. By holding a concentrated position in a company with established credentials in developing treatments for severe diseases, Tubize essentially acts as a conduit for investors to gain exposure to the burgeoning potential of biopharmaceutical advancements. The financial success of Financiere de Tubize SA is intricately tied to the performance of UCB. As UCB thrives and expands through its innovative drug developments and strategic market expansions, Tubize enjoys a consistent flow of dividends and capital appreciation. This dividend income underpins Tubize's operational model, allowing it to reinvest in its core holdings and distribute earnings to its own shareholders, thereby creating a cyclical flow of wealth generation and sustainability. Tubize's approach is akin to a watchful guardian, closely monitoring UCB's strategic paths while maintaining an investment structure that keeps administrative and operational costs minimal. Through such a streamlined focus, Financiere de Tubize SA offers investors a targeted and long-term pathway into the pharmaceutical sector, marked by careful oversight and strategic clarity.

TUB Intrinsic Value
26.33 EUR
Overvaluation 88%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top